Interaction Color Code
Clinical Bottom Line
Do not coadminister: Reduced levels of velpatasvir and voxilapervir
Drug 1
Drug 1 dose
600 mg daily x 14 days
Drug 2
Drug 2 dose
400 / 100 mg daily x 14 days
Drug 2 effect
Velpatasvir AUC decreased 53%, Cmin 57%, Cmax decreased 47%. Sofobuvir Cmax increased 38%.
Clinical Effects
Reduced levels of velapatasvir
Management
Contraindicated. Use alternative agents.
Import ID
464
